



Q2 2020 RESULTS



“ As we continue to face the global COVID-19 pandemic, I’m proud to say that Sanofi’s employees once again put patients first while remaining focused on following through on our strategic priorities in the second quarter. ”

PAUL HUDSON

CHIEF EXECUTIVE OFFICER, SANOFI

COMPANY SALES & BUSINESS EPS*

Q2 2020 SALES*

€8,207M

-3.4% (-4.9%)

Q2 2020 BUSINESS EPS*

€1.28

+4.8% (+3.2%)

*Growth rates are expressed at constant exchange rates (CER). Growth rates in parentheses are expressed on a reported basis.



€2,707M

Specialty Care



€927M

Vaccines

SALES BY GLOBAL BUSINESS UNIT



€3,549M

General Medicines



€1,024M

Consumer Healthcare

SALES BY GEOGRAPHY

U.S

€2,909M

EUROPE

€1,963M

REST OF THE WORLD

€3,335M

of which
China: **€627M**
Japan: **€421M**
Brazil: **€190M**
Russia: **€170M**

EXECUTION OF STRATEGY



New executive team completed with **4 more appointments**



3 product approvals and key R&D milestones achieved



3 collaborations signed in line with Sanofi’s new approach to R&D



Acceleration of **COVID-19 vaccine** candidate development

For further information on Q2 2020 results and definitions of financial indicators, please refer to the press release issued on July 29, 2020 at:
<https://www.sanofi.com/en/investors>



Sanofi.com

Sanofi.us



@Sanofi



Sanofi



@Sanofi



@SanofiUS



SanofiUS